Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19.
HOUSTON–(BUSINESS WIRE)–Vyripharm biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, a privately held company located in the Texas Medical Center in Houston, Texas, announced today that it has signed off on a Master Drug Program Agreement with Regis Technologies, Inc.
Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19.
HOUSTON–(BUSINESS WIRE)–Vyripharm biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, which is a privately held company located in the Texas Medical Center in Houston Texas, announced today that it will repurpose the development of a novel theranostic platform for the diagnosis, monitoring and treatment of viral infections such as SARS, MERS and